Rheumatoid arthritis disease activity and adverse events in patients receiving tofacitinib or tumor necrosis factor inhibitors: a post hoc analysis of ORAL Surveillance.

ABSTRACT:

Background

In patients with rheumatoid arthritis (RA), persistent inflammation and increasing disease activity are associated with increased risk of adverse events (AEs).

Objectives

To assess relationships between RA disease activity and AEs of interest in patients treated with tofacitinib or tumor necrosis factor inhibitors (TNFi).

Design

This was a post hoc analysis of a long-term, postauthorization safety endpoint trial of tofacitinib versus TNFi.

Methods

In ORAL Surveillance, 4362 patients aged ⩾50 years with active RA despite methotrexate, and ⩾1 additional cardiovascular (CV) risk factor, were randomized 1:1:1 to tofacitinib 5 or 10 mg twice daily or TNFi for up to 72 months. Post hoc time-dependent multivariable Cox analysis evaluate

SUBMITTER: Karpouzas GA 

PROVIDER: S-EPMC10629315 | biostudies-literature | 2023

REPOSITORIES: biostudies-literature